Risk of Parkinson's Disease after Tamoxifen Treatment


Show simple item record

dc.contributor.author Latourelle, Jeanne C en_US
dc.contributor.author Dybdahl, Merete en_US
dc.contributor.author Destefano, Anita L en_US
dc.contributor.author Myers, Richard H en_US
dc.contributor.author Lash, Timothy L en_US
dc.date.accessioned 2011-12-29T22:21:53Z
dc.date.available 2011-12-29T22:21:53Z
dc.date.copyright 2010 en_US
dc.date.issued 2010-4-12 en_US
dc.identifier.citation Latourelle, Jeanne C, Merete Dybdahl, Anita L Destefano, Richard H Myers, Timothy L Lash. "Risk of Parkinson's disease after tamoxifen treatment" BMC Neurology 10:23. (2010) en_US
dc.identifier.issn 1471-2377 en_US
dc.identifier.uri http://hdl.handle.net/2144/2570
dc.description.abstract BACKGROUND: Women have a reduced risk of developing Parkinson's disease (PD) compared with age-matched men. Neuro-protective effects of estrogen potentially explain this difference. Tamoxifen, commonly used in breast cancer treatment, may interfere with the protective effects of estrogen and increase risk of PD. We compared the rate of PD in Danish breast cancer patients treated with tamoxifen to the rate among those not treated with tamoxifen. METHODS: A cohort of 15,419 breast cancer patients identified from the Danish Breast Cancer Collaborative Group database was linked to the National Registry of Patients to identify PD diagnoses. Overall risk and rate of PD following identification into the study was compared between patients treated with tamoxifen as adjuvant hormonal therapy and patients not receiving tamoxifen. Time-dependent effects of tamoxifen treatment on PD rate were examined to estimate the likely induction period for tamoxifen. RESULTS: In total, 35 cases of PD were identified among the 15,419 breast cancer patients. No overall effect of tamoxifen on rate of PD was observed (HR = 1.3, 95% CI: 0.64-2.5), but a PD hazard ratio of 5.1 (95% CI: 1.0-25) was seen four to six years following initiation of tamoxifen treatment. CONCLUSIONS: These results provide evidence that the neuro-protective properties of estrogen against PD occurrence may be disrupted by tamoxifen therapy. Tamoxifen treatments may be associated with an increased rate of PD; however these effects act after four years, are of limited duration, and the adverse effect is overwhelmed by the protection against breast recurrence conferred by tamoxifen therapy. en_US
dc.description.sponsorship Public Health Service(R01 NS36711-09); Aahus University Hospital Department of Clinincal Epidemiology's Research Foundation en_US
dc.language.iso en en_US
dc.publisher BioMed Central en_US
dc.rights Copyright 2010 Latourelle et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. en_US
dc.rights.uri http://creativecommons.org/licenses/by/2.0 en_US
dc.title Risk of Parkinson's Disease after Tamoxifen Treatment en_US
dc.type article en_US
dc.identifier.doi 10.1186/1471-2377-10-23 en_US
dc.identifier.pubmedid 20385012 en_US
dc.identifier.pmcid 2862029 en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search OpenBU

Advanced Search


Deposit Materials